Bright Minds Biosciences Inc.
DRUG
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
| Total Depreciation and Amortization | 207.07% | -56.80% | -61.08% | -64.99% | -58.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.96% | -136.47% | -181.23% | -29.72% | 99.59% |
| Change in Net Operating Assets | -66.64% | 37.51% | -238.21% | 103.81% | -266.17% |
| Cash from Operations | -193.39% | 12.08% | 52.42% | 73.75% | 67.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -11.76% | -8.27% | -5.89% | -4.41% | -22.18% |
| Issuance of Common Stock | 5,435.32% | 5,434.34% | 5,406.57% | -38.81% | -87.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -99.96% | -100.00% |
| Cash from Financing | 6,148.59% | 6,147.96% | 6,114.76% | -63.06% | -89.17% |
| Foreign Exchange rate Adjustments | 583.13% | 2,176.35% | 2,113.38% | 124.78% | -198.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,330.33% | 1,378.07% | 1,203.99% | 78.99% | -377.85% |